Jan Van Hattum, Geziena M. Th. Schreuder, Solko W. Schalm – 1 January 1987 – The course after hepatitis B virus infection seems to be determined by the host's immune response, which in turn may be regulated by the major histocompatibility complex. In order to find a possible relationship between the course of disease and the phenotype frequency of HLA determinants, we studied 396 Dutch subjects of northern European local race. Six groups of individuals with various courses after hepatitis B virus infection were compared to healthy controls.

Atsushi Kanno, Hitoshi Ohori, Keizaburoh Matsuda, Haruo Nakayama, Yutaka Miyazaki, Motoyasu Ishii, Hiroshi Suzuki, Masao Ohtsuki, Yoshio Goto – 1 January 1987 – In order to establish the virological significance of HBeAg subtypes (HBeAg/1 and HBeAg/2) during hepatitis B virus infection, HBsAg, HBeAg and hepatitis B virus DNA in serum and HBeAg in liver were determined quantitatively in relation to the detection of HBeAg subtypes in agar gel diffusion.

Yun‐Fan Liaw, Dar‐In Tai, Chia‐Ming Chu, Chia C. Pao, Tong‐Jong Chen – 1 January 1987 – The incidence, clinicopathological features and etiology of acute exacerbation occurring in patients with chronic type B hepatitis were assessed prospectively among 385 patients who had HBeAg and 279 who had anti‐HBe in serum. During an average follow‐up of 23.5 months, acute exacerbations occurred in 197 HBeAg‐positive patients and in 56 anti‐HBe positive patients, with a calculated annual incidence of 28.6 and 10.3%, respectively (p < 0.001).

1 January 1987

S. W. Hosking, A. G. Johnson – 1 January 1987

Boris H. Ruebner, Mary Patricia Pauly, Neville Pimstone, Richard E. Ward, John M. Vierling, Robert H. Fennell, Antonio Monarca, Roberto Natangelo, Valeria Azzolini, B. A. Runyon, Y. Peled, J. Rattan, T. Gilat, Z. Fireman – 1 January 1987

Richard H. Goodman, Andrew Leiter, Malcolm J. Low, Marc R. Montminy, Toshihiko Tsukada, J. Stephen Fink, Gail Mandel – 1 January 1987

David H. Van Thiel, Judy S. Gavaler – 1 January 1987

Katsutaro Hirota, Averell H. Sherker, Masao Omata, Osamu Yokosuka, Kunio Okuda – 1 January 1987 – Adenine arabinoside is an antiviral agent which has been used in a number of clinical studies for the treatment of chronic infections with hepatitis B virus. In order to better understand its effects and mode of action, we treated ducks chronically infected with duck hepatitis B virus with a 2‐week course and monitored the effects of the drug on viral replication by studying duck hepatitis B virus DNA in liver and serum using molecular biological techniques.

Kim Krogsgaard, Bjarne ÖRskov Lindhardt, Jens Ole Nielsen, Poul Andersson, Peter Kryger, Jan Aldershvile, Jan Gerstoft, Court Pedersen – 1 January 1987 – The presence of antibodies to HTLV‐III and markers of active hepatitis B virus replication was examined in a longitudinal study of 33 consecutive male homosexual HBsAg carriers. The mean follow‐up time was 37 months (range = 4 to 109 months). All patients were initially hepatitis B virus DNA‐positive and HBeAg positive. Antibodies to HTLV‐III were detectable in eight patients while they were positive for both of these markers.